A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy

Completed

Conditions studied: Narcolepsy

In brief

The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the impact of transitioning from Xyrem to Xywav in a real-world setting.

Key facts

Study ID

NCT04803786

Run by

Jazz Pharmaceuticals

People needed

110

Starts

2021-04-09

Expected to finish

2022-02-24

Last updated by the study team

2022-06-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, aged 18 years or older
• Diagnosis of type 1 or type 2 narcolepsy by a physician
• Active prescription for Xyrem with a stable treatment regimen for at least 2 consecutive months
• Transitioning from Xyrem to Xywav within the next or past 7 days (- 7 days or + 7 days from the first dose of Xywav)
• Able to read and understand English
• Able to access to a computer/smart phone with internet connection
• Not currently a Jazz Pharmaceuticals employees or an immediate family member of a Jazz employee
• Willing and able to comply with the study schedule
• Willing and able to provide electronically written informed consent

Where it is running

• Jazz Pharmaceuticals Clinical Site — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.